Spots Global Cancer Trial Database for PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2
Official Title: A Phase I, Open Label, Dose-escalating Study of the Proteasome Inhibitor PS-341 in Combination With Two Schedules of Herceptin, in Patients With Advanced Breast Cancer That Overexpresses HER-2
Study ID: NCT00199212
Conditions
Interventions
Study Description
Brief Summary: The main objective of this study is to determine the feasibility of the combination of the proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin) and to determine the best dose of bortezomib to combine with two trastuzumab schedules, weekly and 3-weekly.
Detailed Description: Phase 1 study to determine the feasibility of the combination of the proteasome inhibitor bortezomib (PS-341, Velcade) with trastuzumab (Herceptin) given either weekly or 3-weekly. Additionally, hints about efficacy of the combination will be looked upon.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Jules Bordet Institute, Brussels, , Belgium
Contact Details
Name: Fatima Cardoso, MD
Affiliation: Jules Bordet Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
